Search research articles
Contact Us
Filters
Showing results (131-140 of 144) with videos related to
Page
of 15
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 1, 1996
2-chlorodeoxyadenosine (2-CDA) therapy in previously untreated patients with follicular stage III-IV non-Hodgkin's lymphoma
D C Betticher, E Zucca, A von Rohr, et al.
Lung Cancer (Amsterdam, Netherlands)
|
September 7, 2016
Erlotinib has comparable clinical efficacy to chemotherapy in pretreated patients with advanced non-small cell lung cancer (NSCLC): A propensity-adjusted, outcomes research-based study
P Neumair, L Joos, R Warschkow, et al.
British Journal of Cancer
|
February 4, 2010
Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: A pharmacokinetic-pharmacodynamic analysis from the IELSG no. 20 trial
M Joerger, A D R Huitema, S Krähenbühl, et al.
British Journal of Haematology
|
December 31, 1997
Cladribine (2-CDA) given as subcutaneous bolus injections is active in pretreated Waldenström's macroglobulinaemia. Swiss Group for Clinical Cancer Research (SAKK)
D C Betticher, S F Hsu Schmitz, D Ratschiller, et al.
The Annals of Thoracic Surgery
|
May 22, 1998
Isolated lung perfusion: single-pass system versus recirculating blood perfusion in pigs
M Furrer, D Lardinois, W Thormann, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 18, 1998
Reduced dose of subcutaneous cladribine induces identical response rates but decreased toxicity in pretreated chronic lymphocytic leukaemia. Swiss Group for Clinical Cancer Research (SAKK)
D C Betticher, D Ratschiller, S F Hsu Schmitz, et al.
British Journal of Cancer
|
January 10, 2008
Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study
F Strasser, T A Lutz, M T Maeder, et al.
British Journal of Cancer
|
April 1, 2004
Capecitabine in hormone-resistant metastatic prostatic carcinoma - a phase II trial
R Morant, J Bernhard, D Dietrich, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 21, 1998
Fewer infections, but maintained antitumor activity with lower-dose versus standard-dose cladribine in pretreated low-grade non-Hodgkin's lymphoma
D C Betticher, A von Rohr, D Ratschiller, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 21, 2005
Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group for Clinical Cancer Research (SAKK)
M Ghielmini, K Rufibach, G Salles, et al.
Page
of 15
Search research articles
Search
Showing results (131-140 of 144) with videos related to
Sort By:
Page
of 15
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 1, 1996
2-chlorodeoxyadenosine (2-CDA) therapy in previously untreated patients with follicular stage III-IV non-Hodgkin's lymphoma
D C Betticher, E Zucca, A von Rohr, et al.
Lung Cancer (Amsterdam, Netherlands)
|
September 7, 2016
Erlotinib has comparable clinical efficacy to chemotherapy in pretreated patients with advanced non-small cell lung cancer (NSCLC): A propensity-adjusted, outcomes research-based study
P Neumair, L Joos, R Warschkow, et al.
British Journal of Cancer
|
February 4, 2010
Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: A pharmacokinetic-pharmacodynamic analysis from the IELSG no. 20 trial
M Joerger, A D R Huitema, S Krähenbühl, et al.
British Journal of Haematology
|
December 31, 1997
Cladribine (2-CDA) given as subcutaneous bolus injections is active in pretreated Waldenström's macroglobulinaemia. Swiss Group for Clinical Cancer Research (SAKK)
D C Betticher, S F Hsu Schmitz, D Ratschiller, et al.
The Annals of Thoracic Surgery
|
May 22, 1998
Isolated lung perfusion: single-pass system versus recirculating blood perfusion in pigs
M Furrer, D Lardinois, W Thormann, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 18, 1998
Reduced dose of subcutaneous cladribine induces identical response rates but decreased toxicity in pretreated chronic lymphocytic leukaemia. Swiss Group for Clinical Cancer Research (SAKK)
D C Betticher, D Ratschiller, S F Hsu Schmitz, et al.
British Journal of Cancer
|
January 10, 2008
Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study
F Strasser, T A Lutz, M T Maeder, et al.
British Journal of Cancer
|
April 1, 2004
Capecitabine in hormone-resistant metastatic prostatic carcinoma - a phase II trial
R Morant, J Bernhard, D Dietrich, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 21, 1998
Fewer infections, but maintained antitumor activity with lower-dose versus standard-dose cladribine in pretreated low-grade non-Hodgkin's lymphoma
D C Betticher, A von Rohr, D Ratschiller, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 21, 2005
Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group for Clinical Cancer Research (SAKK)
M Ghielmini, K Rufibach, G Salles, et al.
Page
of 15